Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer

NCT02625441 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

516

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pertuzumab
DRUG: Trastuzumab

Sponsor

Helsinki University Central Hospital